JAMA Oncology | Research Letter
Online First 06/28/2018
doi:10.1001/jamaoncol.2018.2657

Phase I trial evaluating talazoparib, gemcitabine, and olaparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma

Grace M. O'Reilly, MBBS(Hons), MD(Res), FRACP, FCPS(Med Onc), Steven J. Lord, BMedSci(Hons), PhD, Kate Wheeler, BMedSci(Hons), MBBS, Ben Tran, MBBS, PhD, Ian Collins, MBBS, PhD, Michael Jeffrey, MBBS, FRACS, Mark Rischin, MBBS, FRANZCR, PhD, Ben Ellison, MBBS, FRANZCR, Mark Frick, MBBS, FRANZCR

This study was funded by the Lustgarten Foundation, the David M. Rubenstein Center for Pancreatic Cancer Research, and the National Cancer Institute via the Cancer Therapy Evaluation Program (which also provided veliparib), Cancer Support Grant P30 CA008748, and grant R25CA020449.

CONFLICT OF INTEREST DISCLOSURES

Maeve A. Lowery reports working on advisory boards for Agios Pharmaceuticals and Celgene outside the submitted work. Neesha Dhani reports grants and personal fees from Celgene and personal fees from Shire outside the submitted work. Eileen M. O'Reilly reports working on advisory boards for Celgene and Halozyme outside the supported work.

AUTHOR CONTRIBUTIONS

Eileen M. O'Reilly: Conceptualization; design; conduct of the clinical investigation; funding support; data collection; interpretation; and preparation, writing, review, and editing of the manuscript. **Jonathan W. Lee:** Preparation, writing, review, and editing of the manuscript. **Maeve A. Lowery:** Conceptualization; design; conduct of the clinical investigation; funding support; data collection; interpretation; and preparation, writing, review, and editing of the manuscript. **Marinela Capanu:** Preparation, writing, review, and editing of the manuscript. **Zsofia K. Stadler:** Preparation, writing, review, and editing of the manuscript. **Malcolm J. Moore:** Preparation, writing, review, and editing of the manuscript. **Neesha Dhani:** Preparation, writing, review, and editing of the manuscript. **Hedy L. Kindler:** Preparation, writing, review, and editing of the manuscript. **Hayley Estrella:** Preparation, writing, review, and editing of the manuscript. **Hannah Maynard:** Preparation, writing, review, and editing of the manuscript. **Talia Golan:** Preparation, writing, review, and editing of the manuscript. **Amiel Segal:** Preparation, writing, review, and editing of the manuscript. **Erin E. Salo-Mullen:** Preparation, writing, review, and editing of the manuscript. **Kenneth H. Yu:** Preparation, writing, review, and editing of the manuscript. **Andrew S. Epstein:** Preparation, writing, review, and editing of the manuscript. **Michal Segal:** Preparation, writing, review, and editing of the manuscript. **Robin Brenner:** Preparation, writing, review, and editing of the manuscript. **Richard K. Do:** Preparation, writing, review, and editing of the manuscript. **Alice P. Chen:** Preparation, writing, review, and editing of the manuscript. **Laura H. Tang:** Preparation, writing, review, and editing of the manuscript. **David P. Kelsen:** Conceptualization; design; conduct of the clinical investigation; funding support; data collection; interpretation; and preparation, writing, review, and editing of the manuscript.

REFERENCES

Citing Literature

We recommend

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
Anita A. Turk et al., Cancer, 2018

Gemcitabine and platinum combinations in pancreatic cancer
Philip Agop Philip et al., Cancer, 2002

A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma
Maeve A. Lowery et al., Cancer, 2017

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies
Kalen J. Rimar et al., Cancer, 2017

A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer
Weijing Sun et al., Cancer, 2007

Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation
Xue-Song Zhao et al., Chinese Medical Journal, 2019

PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
Pooja Murthy1 et al., Cancer Drug Resistance, 2019

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
Thales Paulo Batista et al., Cancer Drug Resistance-OAE Publishing, 2020

Recent advancements in PARP inhibitors-based targeted cancer therapy
Ping Zhou et al., Precision Clinical Medicine, 2020

Structural basis for allosteric PARP-1 retention on DNA breaks
Levani Zandarashvili et al., Science, 2020

Powered by TREND MD

Download PDF

ACS JOURNALS

News | Jobs | Advertise | Permissions

Copyright © American Cancer Society

About Wiley Online Library

Privacy Policy
Terms of Use
Cookies
Accessibility

Help & Support

Contact Us
DMCA & Reporting Piracy

Opportunities

Subscription Agents
Advertisers & Corporate Partners

Connect with Wiley

The Wiley Network
Wiley Press Room

Copyright © 1999-2021 John Wiley & Sons, Inc. All rights reserved

WILEY